Bausch + Lomb Corp. Q1 2025 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Bausch + Lomb Corporation (BLCO) is a global eye health company operating in three segments: Vision Care, Pharmaceuticals, and Surgical. The company remains a subsidiary of Bausch Health Companies Inc. (BHC), which holds approximately 88% of outstanding shares. The company is actively pursuing a separation from BHC, contingent on achieving targeted debt leverage ratios.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenues | $1,137 | $1,099 |
| Operating (Loss) Income | $(83) | $6 |
| Net Loss | $(211) | $(163) |
| Net Loss Attributable to BLCO | $(212) | $(167) |
| Loss Per Share (Basic & Diluted) | $(0.60) | $(0.48) |
| Operating Cash Flow | $(25) | $41 |
| Total Debt (Principal) | $4,881 | $4,841 |
| Cash and Cash Equivalents | $202 | $305 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 3% ($38 million) year-over-year, driven by volume increases ($63 million) and acquisitions ($6 million), partially offset by unfavorable foreign currency impacts ($19 million) and pricing pressures ($11 million).
- Profitability Decline: The company reported an operating loss of $83 million compared to operating income of $6 million in Q1 2024. This $89 million deterioration was primarily due to increased SG&A expenses and a decrease in contribution margin.
- Segment Performance:
- Vision Care: Revenue up 3% ($656M); Segment profit slightly down to $176M.
- Pharmaceuticals: Revenue flat ($267M); Segment profit dropped significantly to $11M (from $53M) due to pricing pressures on XIIDRA and higher marketing spend for MIEBO.
- Surgical: Revenue up 9% ($214M); Segment profit turned negative at $(7)M (from $11M) largely due to a $15 million inventory reserve charge related to a product recall.
- Unusual Items:
- enVista IOL Recall: A voluntary recall of certain enVista intraocular lenses resulted in a $15 million inventory reserve charge and impacted Surgical segment profitability.
- Acquisition Costs: The company expensed $28 million in acquired in-process research and development (IPR&D) costs related to the acquisition of Whitecap Biosciences.
Guidance, Outlook, and Risks
Management Commentary: Management expects to return to full market supply of enVista IOLs in the U.S. within weeks following the implementation of enhanced inspection protocols. The company continues to monitor the impact of U.S. tariffs and trade restrictions, noting potential actions to mitigate costs through inventory stocking and manufacturing shifts.
Separation from BHC: The proposed separation remains subject to achieving targeted debt leverage ratios and regulatory approvals. There is no assurance the separation will be consummated or the form it will take.
Key Risks:
- Product Recall: Risks associated with the timing of market re-entry for enVista IOLs and potential regulatory actions.
- Trade Policy: Exposure to U.S. tariffs, counter-tariffs, and global supply chain disruptions.
- Legal Proceedings: Ongoing antitrust litigation regarding generic pricing and product liability suits (e.g., Shower to Shower talc litigation, though indemnified by J&J).
- Debt Covenants: The company is currently compliant with financial covenants but faces significant debt maturities in 2027 and 2028.
Investor Verification Checklist
- Verify the timeline and financial impact of the enVista IOL recall resolution and market re-entry.
- Monitor the company's ability to meet debt leverage ratios required for the separation from BHC.
- Assess the sustainability of Pharmaceutical segment margins given pricing pressures on XIIDRA and high marketing spend for MIEBO.
- Review the status of antitrust litigation and potential liability exposure despite indemnification agreements.
- Track the integration and commercialization progress of recent acquisitions, specifically Whitecap Biosciences and Elios Vision.